7,410 Shares in Merck & Co., Inc. $MRK Purchased by USA Financial Formulas

USA Financial Formulas acquired a new position in Merck & Co., Inc. (NYSE:MRK) in the 1st quarter, HoldingsChannel reports. The fund acquired 7,410 shares of the company’s stock, valued at approximately $891,000.

Several other large investors have also modified their holdings of MRK. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter worth approximately $25,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Prosperity Bancshares Inc purchased a new position in Merck & Co., Inc. during the 4th quarter valued at $26,000. High Note Wealth LLC boosted its holdings in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. in the 4th quarter valued at $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized cancer therapy met key Phase 3 goals, improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. The result is the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications. MRK/MRNA’s Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Several Wall Street firms raised their outlooks for MRK: Goldman Sachs increased its price target to $160 and kept a Buy rating, while BMO raised its target to $170 and UBS lifted its target to $175. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.
• Positive Sentiment: Investors see Merck’s newer products, acquired assets and pipeline programs as a potential growth cushion against Keytruda’s eventual patent expiration. The company’s expanding portfolio could help diversify revenue beyond its flagship drug. Can Merck’s New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates heightened investor interest and potential volatility, but it does not by itself establish the direction of the stock.
• Negative Sentiment: RBC Capital Markets downgraded Merck to Sector Perform and set a $150 target, arguing that execution risks and the 2028 Keytruda loss of exclusivity are being underestimated. RBC said near-term catalysts are attractive, but the stock’s valuation leaves limited room for additional gains. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Negative Sentiment: Jefferies separately moved Merck from Strong Buy to Hold. The central concern is that the shares have already rallied substantially on the trial news, making the current valuation appear demanding relative to the remaining patent and execution risks.

Insider Activity

In related news, EVP Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the sale, the executive vice president directly owned 46,613 shares in the company, valued at $6,106,303. The trade was a 24.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP David Michael Williams sold 52,847 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 228,238 shares of company stock valued at $29,977,783. Company insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on MRK shares. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a research note on Wednesday, August 12th. Citigroup assumed coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price for the company. BMO Capital Markets upped their price target on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday. Wells Fargo & Company raised their price target on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 8th. Finally, Royal Bank Of Canada downgraded shares of Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and raised their price target for the stock from $142.00 to $150.00 in a research note on Thursday. Fifteen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $144.10.

Merck & Co., Inc. Stock Up 2.3%

Shares of NYSE:MRK opened at $152.43 on Friday. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $154.49. The stock has a market cap of $376.07 billion, a P/E ratio of 121.94, a price-to-earnings-growth ratio of 6.58 and a beta of 0.19. The business’s 50 day moving average is $128.09 and its 200 day moving average is $121.23. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.Merck & Co., Inc.’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the business posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.2%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 272.00%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.